Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.
A study was undertaken in 24 Chinese patients on maintenance continuous ambulatory peritoneal dialysis, using bezafibrate in its sustained-release form to correct lipid abnormalities. Six patients who received 400 mg/day developed severe muscle weakness with grossly elevated creatine phosphokinase activities within 3 weeks. The drug was discontinued and the symptoms disappeared. The remaining 18 patients received 400 mg/week for 8 weeks. There was a significant decrease in serum triglyceride (2.74 +/- 0.33 to 1.86 +/- 0.17 mmol/l at the 4th week and 1.65 +/- 0.4 mmol/l at the 8th week). Concomitantly, serum total cholesterol decreased. Serum high-density lipoprotein cholesterol increased significantly (from 1.18 +/- 0.082 to 1.36 +/- 0.060 mmol/l at the 4th week and 1.40 +/- 0.103 mmol/l at the 8th week). Post-heparin lipoprotein and hepatic lipases were measured by a substrate-specific method. The former increased significantly (p = 0.000) after bezafibrate treatment while the latter did not change. All parameters of lipid metabolism returned towards baseline 4 weeks after discontinuation of therapy. The drug was well tolerated at 400 mg/week and there was no significant rise in serum creatine phosphokinase.
Chan
M K
MK
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control; D003692:Delayed-Action Preparations; D048909:Diabetes Complications; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*
D008076:Cholesterol, HDL; D003692:Delayed-Action Preparations; D008055:Lipids; D001629:Bezafibrate